Ranibizumab-related improvements in diabetic retinopathy (DR) severity continue in >70 percent of patients in the open-label extension (OLE) of the RIDE and RISE studies after switching from ranibizumab monthly to an individualized ranibizumab 0.5 mg pro re nata (PRN) dosing regimen.
High-dose cyclosporine A (CsA) cationic emulsion (CE) is well tolerated and effective in improving keratitis, symptoms and quality of life (QOL) in patients with severe vernal keratoconjunctivitis (VKC), according to a phase III study.
Parafoveal flow and vessel density (VD) are significantly reduced in individuals with early cognitive impairment and may serve as early biomarkers for Alzheimer’s disease (AD), according to a recent study.
Adding rescue photodynamic therapy (rPDT) to treatment with the anti-VEGF agent aflibercept intravitreally did not provide additional benefit for patients with polypoidal choroidal vasculopathy (PCV), a type of neovascular age-related macular degeneration (nAMD), according to the PLANET study, suggesting that aflibercept monotherapy sufficed for these patients.
Once-daily dosing of the Rho kinase inhibitor netarsudil is not inferior to twice-daily timolol in terms of lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, while having tolerable adverse events, according to the results of the phase III ROCKET-4 trial.
A new study from the UK has suggested that patients recently diagnosed with ocular hypertension or open angle glaucoma (OAG) could derive greater benefit from undergoing selective laser trabeculoplasty (SLT) rather than being treated with intraocular pressure-reducing eye drops.
New drug applications approved by US FDA as of 01 - 15 March 2019 which includes New Molecular Entities (NMEs) and new biologics. It
does not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Long-term monotherapy with intravitreal aflibercept (IAI) is noninferior to IAI with rescue photodynamic therapy (IAI + rPDT) in terms of functional and anatomical improvements in patients with polyploidal choroidal vasculopathy (PCV), a new Singapore analysis of the PLANET* study has found.
Women practicing exclusive breastfeeding for 6 months achieve greater postpartum weight loss compared with those exclusively breastfeeding for a shorter duration, according to data from the MILK* study.